Holen Sie sich die Stockscreener-App
38.64
1.18%
0.45
Vorhandelsmarkt:
38.69
0.05
+0.13%
Schlusskurs vom Vortag:
$38.19
Offen:
$38.67
24-Stunden-Volumen:
1.68M
Relative Volume:
0.52
Marktkapitalisierung:
$4.20B
Einnahmen:
-
Nettoeinkommen (Verlust:
$-95.90M
KGV:
-29.27
EPS:
-1.32
Netto-Cashflow:
$-79.09M
1W Leistung:
+7.15%
1M Leistung:
+8.91%
6M Leistung:
+513.33%
1J Leistung:
+798.60%
1-Tages-Spanne:
$37.02
$39.60
1-Wochen-Bereich:
$34.98
$39.60
52-Wochen-Spanne:
$1.865
$48.26
Terns Pharmaceuticals Inc Stock (TERN) Company Profile
Firmenname
Terns Pharmaceuticals Inc
Sektor
Branche
Telefon
650-525-5535 EXT.101
Adresse
1065 EAST HILLSDALE BLVD., SUITE 100, FOSTER CITY
Compare TERN vs VRTX, REGN, ARGX, ALNY, ONC
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
TERN
Terns Pharmaceuticals Inc
|
38.64 | 4.15B | 0 | -95.90M | -79.09M | -1.32 |
|
VRTX
Vertex Pharmaceuticals Inc
|
461.24 | 117.59B | 11.74B | 3.68B | 3.34B | 14.19 |
|
REGN
Regeneron Pharmaceuticals Inc
|
778.97 | 79.81B | 14.34B | 4.50B | 3.77B | 41.56 |
|
ARGX
Argen X Se Adr
|
834.55 | 51.56B | 3.06B | 1.28B | 447.35M | 19.67 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
322.28 | 42.67B | 3.21B | 43.57M | 221.36M | 0.2405 |
|
ONC
Beone Medicines Ltd Adr
|
351.27 | 39.11B | 4.98B | 69.60M | 525.67M | 0.5198 |
Terns Pharmaceuticals Inc Stock (TERN) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2026-02-09 | Eingeleitet | Leerink Partners | Outperform |
| 2025-11-04 | Hochstufung | H.C. Wainwright | Neutral → Buy |
| 2025-11-03 | Hochstufung | William Blair | Mkt Perform → Outperform |
| 2025-10-15 | Eingeleitet | Truist | Buy |
| 2025-09-17 | Eingeleitet | Barclays | Overweight |
| 2025-09-04 | Fortgesetzt | H.C. Wainwright | Neutral |
| 2025-02-28 | Eingeleitet | William Blair | Mkt Perform |
| 2024-10-31 | Eingeleitet | Oppenheimer | Outperform |
| 2023-06-22 | Eingeleitet | Mizuho | Buy |
| 2023-06-07 | Eingeleitet | Jefferies | Buy |
| 2023-05-31 | Eingeleitet | ROTH MKM | Buy |
| 2023-05-08 | Eingeleitet | BMO Capital Markets | Outperform |
| 2023-02-14 | Eingeleitet | JMP Securities | Mkt Outperform |
| 2023-02-07 | Eingeleitet | UBS | Buy |
| 2022-09-12 | Eingeleitet | H.C. Wainwright | Neutral |
| 2021-09-14 | Fortgesetzt | Goldman | Buy |
| 2021-03-02 | Eingeleitet | Cowen | Outperform |
| 2021-03-02 | Eingeleitet | Goldman | Buy |
| 2021-03-02 | Eingeleitet | JP Morgan | Overweight |
Alle ansehen
Terns Pharmaceuticals Inc Aktie (TERN) Neueste Nachrichten
Leerink Partners Initiates Coverage on Terns Pharmaceuticals With Outperform Rating, $58 Price Target - marketscreener.com
Leerink Partners initiates Terns Pharmaceuticals stock with Outperform rating By Investing.com - Investing.com Canada
Leerink Partners Begins Coverage on Terns Pharmaceuticals (NASDAQ:TERN) - MarketBeat
Leerink Partners initiates Terns Pharmaceuticals stock with Outperform rating - Investing.com
VIX Spike: What are Terns Pharmaceuticals Incs technical support levels2025 Pullback Review & Weekly Sector Rotation Insights - baoquankhu1.vn
Wall Street analysts see a 50.91% upside in Terns Pharmaceuticals (TERN): Can the stock really move this high? - MSN
Cancer index surges 72% as Terns, Olema lead gains - BioWorld MedTech
Wall Street Analysts See a 50.91% Upside in Terns Pharmaceuticals (TERN): Can the Stock Really Move This High? - sharewise.com
Terns Pharmaceuticals, Inc. $TERN Stock Position Increased by AlphaQuest LLC - MarketBeat
A Look At Terns Pharmaceuticals (TERN) Valuation After Expanded TERN-701 Rights And Positive Trial Update - Sahm
Terns Pharmaceuticals (TERN) climbs 53% on stellar leukemia treatment trial - MSN
Terns Pharmaceuticals (TERN) Valuation Check After Expanded Global Rights To TERN-701 - Yahoo Finance
Terns Pharmaceuticals reports inducement grants to new employees under Nasdaq Listing Rule - marketscreener.com
Terns Pharmaceuticals Reports Inducement Grants To New Employees Under Nasdaq Listing Rule - TradingView
Terns Pharmaceuticals Reports Inducement Grants to New Employees Under Nasdaq Listing Rule 5635(C)(4) - The Manila Times
What Terns Pharmaceuticals (TERN)'s Expanded Global Rights to TERN-701 Mean For Shareholders - Sahm
Terns Pharmaceuticals (TERN) Eyes Expansion Beyond China Amid Strong Analyst Sentiment - Finviz
Terns Pharmaceuticals patent discloses GIPR antagonists - BioWorld MedTech
What is Terns Pharmaceuticals Inc. s 5 year growth outlook2025 Historical Comparison & Daily Profit Maximizing Trade Tips - mfd.ru
Terns Pharmaceuticals Expands Global Rights to TERN-701 - TipRanks
Terns Pharmaceuticals, Inc. (NASDAQ:TERN) Receives Average Recommendation of "Moderate Buy" from Analysts - MarketBeat
Novo climbs higher on ‘strong’ Wegovy pill launch; Terns tweaks leukemia drug deal - BioPharma Dive
Terns Pharmaceuticals amends license agreement with Hansoh for TERN-701 rights - Investing.com
What technical signals suggest for Terns Pharmaceuticals Inc. stockQuarterly Trade Summary & Low Risk Profit Maximizing Plans - bollywoodhelpline.com
Wall Street forecasts 42.31% upside to Terns Pharmaceuticals, Inc. (TERN) - MSN
Assessing Terns Pharmaceuticals (TERN) Valuation After New TERN-701 Data And Capital Raise - Sahm
Insider Selling: Terns Pharmaceuticals (NASDAQ:TERN) CEO Sells $2,548,525.43 in Stock - MarketBeat
Wall Street Forecasts 42.31% Upside To Terns Pharmaceuticals, Inc. (TERN) - Finviz
Terns Pharmaceuticals stock jumps 10% as JPM conference puts TERN-701 back on the map - TechStock²
Terns Pharmaceuticals (NASDAQ:TERN) Trading Up 10.4%Should You Buy? - MarketBeat
Aug Patterns: Can Terns Pharmaceuticals Inc stock sustain institutional interestJuly 2025 Final Week & Consistent Profit Trade Alerts - Bộ Nội Vụ
J.P. Morgan: Terns Looks To Take Flight With TERN-701 In 2026 - Citeline News & Insights
William Blair reiterates Outperform rating on Terns Pharmaceuticals stock By Investing.com - Investing.com Canada
Terns Pharmaceuticals (TERN) Valuation After Encouraging TERN 701 CML Data And Capital Raise Powered Development Plans - Yahoo Finance
Citizens Maintains An Outperform Rating On Terns Pharmaceuticals, Inc. (TERN) - Finviz
Terns Pharmaceuticals (NASDAQ:TERN) Trading Down 6.3%Here's Why - MarketBeat
Assessing Terns Pharmaceuticals (TERN) Valuation After Recent Share Price Swings And Elevated Price To Book Ratio - Sahm
Analysts Offer Insights on Healthcare Companies: Anteris Technologies Global Corp. (AVR) and Terns Pharmaceuticals (TERN) - The Globe and Mail
How Rhythm Pharmaceuticals, Inc. stock performs during market volatility - Улправда
Tern Pharmaceuticals (TERN) soars 630% on CML treatment best-in-class potential - MSN
Terns Pharmaceuticals (TERN) price target increased by 75.91% to 54.63 - MSN
Why Terns Pharmaceuticals Inc. stock could see breakout soonEarnings Beat & Consistent Return Investment Signals - ulpravda.ru
Why Terns Pharmaceuticals Inc. stock could be next big winnerEarnings Recap Summary & Daily Entry Point Trade Alerts - Улправда
Will Fast Track TERN-701 Status and $747.5 Million Raise Change Terns Pharmaceuticals' (TERN) Narrative - Sahm
Terns Pharmaceuticals to Highlight 2026 Priorities and Program Milestones at the 44th Annual J.P. Morgan Healthcare Conference - TradingView — Track All Markets
Star Tribune - FinancialContent
New data on CML pill TERN-701 and $1B war chest for next cancer trials - Stock Titan
Finanzdaten der Terns Pharmaceuticals Inc-Aktie (TERN)
Umsatz
Nettogewinn
Free Cashflow
ENV
2.09%
2.01%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):